Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...
Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
GlobalData on MSN11d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Zacks Investment Research on MSN2d
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsThe most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback